Floatz logo

Empagliflozin

Bipolar Disorder

University of Sao PauloSmall moleculeN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
73/ 100

Competitive context

66 Active assets in the Bipolar Disorder cohort.

Asset / SponsorPhaseRating
Asenapine
Dr. Stavroula Rakitzi
Phase 4BBB
LITHIUM, ELEMENTAL
University of Aarhus
Phase 4BBB
Seroquel®
First Affiliated Hospital of Zhejiang University
Phase 4BBB
CITALOPRAM
University of Texas Southwestern Medical Center
Phase 4BBB
Cipralex
First Affiliated Hospital of Zhejiang University
Phase 4BBB

View all 50 →

Same molecule, other indications

Empagliflozin is also rated in:

metabolic dysfunction-associated steatotic liver diseaseDormant
BBB
Indicative ·
76 / 100
View asset →
Hypoglycemic AgentsDormant
BBB
Indicative ·
75 / 100
View asset →
prediabetes syndromeDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →